logo

For the Inventor, By the Inventor

Waterford, CT, United States of America

Christopher A Lipinski

This inventor holds 15 USPTO granted patents, primarily in Diabetes Treatment. Top assignee: Pfizer Corporation. Active years: 1976-1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher A Lipinski. Retrieved from https://idiyas.com/inventor/christopher-a-lipinski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15

% Patents Active = 100.0

Average Co-Inventor Count = 1.3

ph-index = 6

Forward Citations = 84(Granted Patents)


Location History:

  • New London, CT (US) (1988)
  • Waterford, CT (US) (1976 - 1991)

Company Filing History:

goldMedal15 out of 4,492 
 
Pfizer Corporation
 patents

Years Active: 1976-1991

Loading Chart...
Areas of Expertise:
Spiro-Heteroazalones
Diabetes Complications
Aldose Reductase Inhibitors
Hydroxyacetic Acid Derivatives
Spiro-Succinimides
Imidazolylpyridine
Antiulcer Agents
2-Guanidino-4-Heteroarylthiazoles
Pyridylaminotriazole
Therapeutic Agents
Spiro-Imidazolones
5-M-Tolyloxyuracil
15 patents (USPTO):Explore Patents
1. 5066659 - Spiro-heteroazalones for treatment of diabetic complications (1991-11-19),
2. 4853410 - Hydroxyacetic acid derivatives for the treatment of diabetic (1989-08-01),
3. 4766141 - Spiro-succinimides for treatment of diabetes complications (1988-08-23),
4. 4680306 - Sprio-imidazolones for treatment of diabetes complications (1987-07-14),
5. 4590299 - 2-guanidino-4-heteroarylthiazoles (1986-05-20),
6. 4575507 - Spiro-imidazolidines as aldose reductase inhibitors and their (1986-03-11),
7. 4556670 - Spiro-3-hetero-azolones for treatment of diabetic complications (1985-12-03),
8. 4510313 - 2-Guanidino-4-heteroarylthiazoles (1985-04-09),
9. 4452987 - Haloacetyl imidazoles (1984-06-05),
10. 4435396 - Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and (1984-03-06),
11. 4374843 - 2-Guanidino-4-heteroarylthiazoles (1983-02-22),
12. 4302464 - Imidazolylpyridine therapeutic agents (1981-11-24),
13. 4276297 - Pyridylaminotriazole therapeutic agents (1981-06-30),
14. 4080454 - 5-M-Tolyloxyuracil, anti-ulcer agent (1978-03-21),
15. 3941889 - 5-(Substituted phenoxy)-4-amino pyrimidines as anti-ulcer agents (1976-03-02),

Title: The Innovative Contributions of Christopher A. Lipinski

Introduction

Christopher A. Lipinski is a prominent inventor based in Waterford, CT, known for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, Lipinski has made remarkable strides in developing therapeutic agents, particularly for the treatment of diabetic complications.

Latest Patents

Among his latest patents is the invention of spiro-heteroazalones, which serve as aldose reductase inhibitors. These compounds are particularly useful in treating complications arising from diabetes. Additionally, he has developed hydroxyacetic acid derivatives aimed at addressing diabetic conditions. These innovations reflect his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Lipinski is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to collaborate with some of the brightest minds in the industry, further enhancing his contributions to pharmaceutical research and development.

Collaborations

Some of his notable coworkers include John L. LaMattina and John L. La Mattina, who have also made significant contributions to the field. Their collaborative efforts have fostered an environment of innovation and excellence within the pharmaceutical sector.

Conclusion

Christopher A. Lipinski's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and research continue to pave the way for new treatments that can significantly improve the lives of individuals suffering from diabetes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…